Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
Phase 2
Completed
- Conditions
- Ocular Hypertension
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 73
- Registration Number
- NCT00332345
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- Ocular Hypertension
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 573
- Registration Number
- NCT00332384
AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers
- First Posted Date
- 2006-05-15
- Last Posted Date
- 2011-06-02
- Lead Sponsor
- Allergan
- Target Recruit Count
- 150
- Registration Number
- NCT00325715
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
Phase 3
Completed
- Conditions
- Overactive Bladder
- Interventions
- Biological: botulinum toxin Type A (300U)Biological: botulinum toxin Type A (200U)Other: Normal Saline (Placebo); botulinum toxin Type A (200U)Other: Normal Saline (Placebo); botulinum toxin Type A (300U)
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- Allergan
- Target Recruit Count
- 416
- Registration Number
- NCT00311376
Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
Phase 2
Completed
- Conditions
- Ocular Hypertension
- First Posted Date
- 2006-03-09
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 561
- Registration Number
- NCT00300443
Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia
Phase 2
Completed
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Biological: botulinum toxin Type ADrug: normal saline
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 380
- Registration Number
- NCT00284518
A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.
Phase 2
Completed
- Conditions
- Rosacea
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 400
- Registration Number
- NCT00249782
- Locations
- 🇺🇸
University Clinical Research, Inc., Pembroke Pines, Florida, United States
🇺🇸Paddington Testing Co., Inc., Philadelphia, Pennsylvania, United States
🇺🇸Academic Dermatology Associates, Albuquerque, New Mexico, United States
A Multi-Center Randomized Study to Evaluate the Efficacy and Safety of an Investigational Lubricant Eye Drop
Phase 2
Completed
- Conditions
- Dry Eye
- First Posted Date
- 2005-10-25
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 286
- Registration Number
- NCT00243711
Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency
Phase 4
Completed
- Conditions
- Acne Vulgaris
- First Posted Date
- 2005-10-24
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 64
- Registration Number
- NCT00243542
- Locations
- 🇺🇸
Okatie Research Center, LLC, Beaufort, South Carolina, United States
🇺🇸Dermatology Associates, PC at the Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸Dermatology Associates of Knoxville, Knoxville, Tennessee, United States
A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches
Phase 3
Completed
- Conditions
- Migraine Disorders
- Interventions
- Biological: Botulinum Toxin Type AOther: placebo (saline)
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2013-11-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 705
- Registration Number
- NCT00168428
© Copyright 2025. All Rights Reserved by MedPath